<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892110</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00058198</org_study_id>
    <secondary_id>UG3DA043231</secondary_id>
    <nct_id>NCT02892110</nct_id>
  </id_info>
  <brief_title>Varenicline Treatment for Cannabis Use Disorder</brief_title>
  <official_title>Advancing Varenicline as a Treatment for Cannabis Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marijuana is the most commonly used illicit drug. There is high demand for effective
      interventions for cannabis use disorder, yet few specific treatments for have been developed.
      This study will evaluate the efficacy of varenicline for reducing marijuana use in people who
      use marijuana frequently.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Actual">November 27, 2018</completion_date>
  <primary_completion_date type="Actual">November 8, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis Withdrawal Symptoms During Active Treatment</measure>
    <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
    <description>For this outcome, the negative affect subscale items of The Cannabis Withdrawal Scale (items 5 [&quot;I felt nervous], 6 [&quot;I had some angry outbursts&quot;], 7 [&quot;I had mood swings&quot;], 8 [&quot;I felt depressed&quot;], 9 [&quot;I was easily irritated&quot;], 15 [&quot;Life seemed an uphill struggle&quot;], 18 [&quot;I felt physically tense&quot;], restlessness (item 11, &quot;I felt restless), and/or urge to smoke (items 1 and 10, &quot;The only thing I could think about was smoking some cannabis&quot; and &quot;I had been imagining being stoned&quot;) were averaged at Weeks 4, 5, and 6 and for an overall 4-6 week value, with minimum score of the subscale being 0 and maximum score being 100 (higher score indicating worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cannabis Abstinence</measure>
    <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
    <description>Self reported abstinence from Timeline Followback, verified by urine cannabinoid measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabis Use Quantity</measure>
    <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
    <description>Cannabis use sessions per day measured by Timeline Followback (self-report) at twice weekly visits during Weeks 4, 5 and 6 of the active treatment phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Substance Use Disorder</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>2 mg daily</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mg daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria

          -  Must meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days
             per week in the last 30 days.

          -  Must be between the ages of 18 and 65 years.

          -  If female and of childbearing potential, must agree to use acceptable methods of birth
             control for the duration of the trial.

          -  Must consent to random assignment, and be willing to commit to medication ingestion.

          -  Must be able to read and provide informed consent.

          -  Must have body weight &gt;110lbs (50kg) and have BMI between 18 and 35kg/m2

          -  Must function at an intellectual level and have knowledge of the English language to
             sufficiently allow for accurate completion of assessments.

        Additional Inclusion Criteria for fMRI Eligibility

        â€¢ Must be right-handed.

        General Exclusion Criteria

          -  Women who are pregnant, nursing, or plan to become pregnant during the course of the
             study.

          -  Individuals with severe renal impairment (creatinine clearance less than 30 mL per
             minute).

          -  Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic
             disorder. Stably treated MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia
             diagnoses are acceptable (i.e. same dose of medication has been prescribed for at
             least 2 months prior to screening and no changes in current medication expected during
             course of the trial).

          -  Suicidal ideation or behavior within the past 6 months. Subjects who are believed to
             be at suicidal or homicidal risk (answers 'yes' on questions 4 or 5 of C-SSRS) will be
             referred for assessment by a qualified mental health professional.

          -  Concomitant use of psychotropic medications, with the exception of stable doses
             (defined as no dosing adjustments in the past two months) of non-MAO-I
             antidepressants, non-benzodiazepine anxiolytics, and ADHD medications.

          -  Current use of medications prescribed for mania or psychosis.

          -  Current use of buproprion or nortryptiline.

          -  Moderate or severe non-cannabis substance use disorders within the past 60 days with
             the exception of tobacco use disorder.

          -  Individuals taking an investigational agent within the last 30 days before baseline
             visit.

          -  Individuals with clinically significant medical disorders or lab abnormalities.

          -  Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the
             upper limit of normal and/or total bilirubin greater than two times the upper limit of
             normal.

          -  Individuals with clinically significant cardiovascular disease in the past 6 months
             (e.g., myocardial infarction, CABG, PTCA, severe or unstable angina, serious
             arrhythmia, or any clinically significant ECG conduction abnormality.

          -  Individuals with clinically significant cerebrovascular disease in the past 6 months
             such as TIA, CVA, or stroke.

          -  Hypersensitivity to varenicline.

          -  Individuals who have participated in the clinical trial of any investigative compound
             within the last 60 days.

        Additional Exclusion Criteria for fMRI Eligibility

          -  Any psychiatric or medical issues, including claustrophobia, ferrous metal implants,
             pacemakers, or other electronic devices that would interfere with ability to
             participate in and successfully complete scanning procedures.

          -  Any person unable to lie still within the fMRI scanner for the required period of time
             to obtain useful images (use of anxiolytics will not be permitted for
             anxiety/claustrophobia related to scanning procedures).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <results_first_submitted>October 22, 2019</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2019</results_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Marijuana use</keyword>
  <keyword>Varenicline/Chantix</keyword>
  <keyword>Motivational enhancement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02892110/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>2 mg daily
Varenicline: 2 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 mg daily
Placebo: 2 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>2 mg daily
Varenicline: 2 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 mg daily
Placebo: 2 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cannabis Withdrawal Symptoms During Active Treatment</title>
        <description>For this outcome, the negative affect subscale items of The Cannabis Withdrawal Scale (items 5 [&quot;I felt nervous], 6 [&quot;I had some angry outbursts&quot;], 7 [&quot;I had mood swings&quot;], 8 [&quot;I felt depressed&quot;], 9 [&quot;I was easily irritated&quot;], 15 [&quot;Life seemed an uphill struggle&quot;], 18 [&quot;I felt physically tense&quot;], restlessness (item 11, &quot;I felt restless), and/or urge to smoke (items 1 and 10, &quot;The only thing I could think about was smoking some cannabis&quot; and &quot;I had been imagining being stoned&quot;) were averaged at Weeks 4, 5, and 6 and for an overall 4-6 week value, with minimum score of the subscale being 0 and maximum score being 100 (higher score indicating worse outcome).</description>
        <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>2 mg daily
Varenicline: 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg daily
Placebo: 2 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cannabis Withdrawal Symptoms During Active Treatment</title>
          <description>For this outcome, the negative affect subscale items of The Cannabis Withdrawal Scale (items 5 [&quot;I felt nervous], 6 [&quot;I had some angry outbursts&quot;], 7 [&quot;I had mood swings&quot;], 8 [&quot;I felt depressed&quot;], 9 [&quot;I was easily irritated&quot;], 15 [&quot;Life seemed an uphill struggle&quot;], 18 [&quot;I felt physically tense&quot;], restlessness (item 11, &quot;I felt restless), and/or urge to smoke (items 1 and 10, &quot;The only thing I could think about was smoking some cannabis&quot; and &quot;I had been imagining being stoned&quot;) were averaged at Weeks 4, 5, and 6 and for an overall 4-6 week value, with minimum score of the subscale being 0 and maximum score being 100 (higher score indicating worse outcome).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Week 4-6 average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="4.65"/>
                    <measurement group_id="O2" value="3.94" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="6.73"/>
                    <measurement group_id="O2" value="4.07" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="4.84"/>
                    <measurement group_id="O2" value="4.27" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="4.65"/>
                    <measurement group_id="O2" value="3.47" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cannabis Abstinence</title>
        <description>Self reported abstinence from Timeline Followback, verified by urine cannabinoid measures</description>
        <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>2 mg daily
Varenicline: 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg daily
Placebo: 2 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cannabis Abstinence</title>
          <description>Self reported abstinence from Timeline Followback, verified by urine cannabinoid measures</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cannabis Use Quantity</title>
        <description>Cannabis use sessions per day measured by Timeline Followback (self-report) at twice weekly visits during Weeks 4, 5 and 6 of the active treatment phase.</description>
        <time_frame>3 weeks (Week 4-6 of active treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>2 mg daily
Varenicline: 2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg daily
Placebo: 2 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cannabis Use Quantity</title>
          <description>Cannabis use sessions per day measured by Timeline Followback (self-report) at twice weekly visits during Weeks 4, 5 and 6 of the active treatment phase.</description>
          <units>sessions per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.54" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.33" lower_limit="0.96" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.5" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.19" lower_limit="0.82" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.5" upper_limit="1.29"/>
                    <measurement group_id="O2" value="1.21" lower_limit="0.84" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from time of consent through last study visit (approximately 8 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>2 mg daily
Varenicline: 2 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 mg daily
Placebo: 2 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Other GI</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dream disturbance</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="35"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI/cold symptoms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Intended as a proof of concept study; fully powered clinical trials are needed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amanda Wagner, Program Manager</name_or_title>
      <organization>MUSC</organization>
      <phone>843-792-0484</phone>
      <email>wagne@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

